People with cannabis use disorder (CUD) are likely also to have social anxiety disorder (SAD), and comorbid SAD is associated with greater severity of cannabis-related problems. These findings highlight the importance of assessing CUD patients for SAD, as that disorder can be both a contributing cause and a consequence of CUD. Treating both disorders may be a key to helping patients recover from each.
Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.
Regular cannabis use that starts in adolescence strips away IQ, a NIDA-supported study suggests. Participants who initiated weekly cannabis use before age 18 dropped IQ points in proportion to how long they persisted in using the drug. Persistent cannabis users’ cognitive difficulties were evident to friends and family and measurable on a battery of tests.
New research demonstrated that, in rhesus monkeys, ongoing cocaine exposure weakens two brain functions that people require for successful behavioral change: cognitive flexibility and memory. But the study determined that these changes may not be permanent.
Researchers found that 1 in 8 high school seniors had used a prescription opioid nonmedically, and 70 percent of these teens had compounded the attendant risk by co-ingesting an opioid with one or more other drugs. Nonmedical opioid use was significantly more prevalent among whites than among African Americans or Hispanics.
When the goal is to avoid using alcohol and illicit substances after being released from jail, it’s who one’s friends are that counts most. Self-control is important because it helps a person have the right kind of friends.
A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.